<DOC>
	<DOCNO>NCT01836133</DOCNO>
	<brief_summary>This multicenter , observational study evaluate efficacy safety Tarceva ( erlotinib ) patient locally advance metastatic adenocarcinoma non-small cell lung cancer ECOG performance status 0-1 . Eligible patient receive Tarceva accord Summary Product Characteristics local label follow duration treatment .</brief_summary>
	<brief_title>An Observational Study Tarceva ( Erlotinib ) Patients With Locally Advanced Metastatic Adenocarcinoma Non-Small Cell Lung Cancer ( ELEMENT )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Histologically cytologically confirm , locally advanced ( Stage IIIb ) metastatic ( Stage IV ) adenocarcinoma nonsmall cell lung cancer Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Adequate hematologic , renal liver function Patient initiate treatment Tarceva accord Summary Product Characteristics Any contraindication treatment Tarceva accord Summary Product Characteristics local label Any malignancy within previous 5 year , except situ carcinoma cervix basal squamous cell carcinoma skin Previous systemic anticancer treatment HER1/EGFR inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>